Red Oak will do fine because they got in at such a cheap price. They've solidified the balance sheet and aligned Board decision-making with SH interests. That's a good start, but the big question is whether they'll be able to help turnaround and grow the mainline cord blood/tissue storage business. Although not their fault and probably not foreseeable during their due diligence, they had an early set back with the loss of most of the tissue business. They can either proactively try to support management or elect to replace management. In either case if they see operations gaining momentum, they'll probably hold longer and maybe even buy more. If operations sputter and they can't think how to turn it around, they might decide to flip their interest for a quick gain. We know who at least one of the suspected buyers might be.
News 
Market Data 
Discover 
AI
